PIPELINE
Next-generation bispecific antibodies to raise the efficacy bar
At Navigator, we’re advancing a pipeline of expertly engineered bispecific antibodies to deliver effective, well tolerated and convenient options for people living with complex inflammatory diseases.
MAINSAIL is a Phase 2a multi-center, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of NAV-240 in adults living with moderate to severe Hidradenitis Suppurativa (HS).
Efficacy including a reduction in abscesses, nodules, draining tunnels, as well as improvement in quality-of-life outcomes will be assessed.
Full details of the Phase 2a MAINSAIL trial can be accessed at ClinicalTrials.gov (NCT 07384975).